2 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Diffuse Hemispheric Glioma, H3 G34-Mutant: new trials by email Literature Review of Diffuse Hemispheric Glioma, H3 G34-Mutant trials Research Report on Diffuse Hemispheric Glioma, H3 G34-Mutant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours Avutometinib, Defactinib, Temozolomide - Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 182 | 2024-11-15 | 2026-01-21 |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant Ribociclib, Everolimus, Temozolomide (TMZ) - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Recruiting | Nationwide Children's Hospital | 120 | 2024-08-22 | 2026-05-29 |
Glioblastoma (2) · Astrocytoma (1) · Brain Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Glioma (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neoplasms, Neuroepithelial (2) · Neuroectodermal Tumors (2) · Astrocytoma (1) · Brain Diseases (1) · Brain Stem Neoplasms (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Glioma (1) · Infratentorial Neoplasms (1) · Neoplasms by Site (1)
Temozolomide (2) · Everolimus (1) · defactinib (1) · ribociclib (1)
Institute of Cancer Research, United Kingdom (1) · Nationwide Children's Hospital (1)
United Kingdom (2) · Australia (1) · Canada (1) · Germany (1) · New Zealand (1) · United States (1)
Juanita Lopez, MD, PhD (1) · Margot Lazow, MD (1) · Maryam Fouladi, MD (1)